Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course rifapentine regimens and adherence support for latent tuberculosis infection in UK adults
2020-004444-29Phase 4Unknown
- Sponsor
- University College London
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifapentine in latent tuberculosis infection (LTBI) (2 arms), sponsored by University College London. Primary endpoint: Adequate treatment adherence. Status: unknown.
02
Drugs
rifapentine
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2020-004444-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004444-29.